-
Publication Venue For
-
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types..
32:661-672.
2021
-
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.
2021
-
Pan-cancer prognostic models of clinical outcomes: statistical exercise or clinical tools?.
31:1427-1429.
2020
-
TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker..
31:1518-1525.
2020
-
Prognostic gene expression signature for high-grade serous ovarian cancer..
31:1240-1250.
2020
-
Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer..
31:930-941.
2020
-
Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors..
31:626-633.
2020
-
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer..
31:590-598.
2020
-
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations..
31:171-190.
2020
-
Defining sarcoma specialist center: revisiting the volume effect..
30:1840.
2019
-
Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer..
30:1622-1629.
2019
-
Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer..
30:1622-1629.
2019
-
A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who are at high risk of recurrence after curative hepatic resection..
30 Suppl 4:iv51.
2019
-
A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2..
30 Suppl 4:iv59-iv60.
2019
-
Evaluation of the mimetic peptide APOE COG1410 in the viability, migration, and apoptosis of the intestinal cells IEC-18 after injuries by 5-FU..
30 Suppl 4:iv31.
2019
-
Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?.
30:1025-1028.
2019
-
WNT / β-catenin pathway in recovering IEC-6 intestinal cells after 5-FU induced injury and treatment with mimetic peptide APOE COG133..
30 Suppl 4:iv102.
2019
-
Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer..
30:1019.
2019
-
Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia..
30:542-550.
2019
-
The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial..
30:575-581.
2019
-
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge..
30:243-249.
2019
-
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer..
29:2200-2207.
2018
-
GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer.
29:ix86.
2018
-
Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC.
29:ix151-ix152.
2018
-
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness..
29:2271.
2018
-
A phase Ib/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC).
29:viii726.
2018
-
Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial..
29:2098-2104.
2018
-
Association of PD-L1 expression with prognosis among patients with 10 select cancers.
29:viii15.
2018
-
Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214.
29:viii309-viii310.
2018
-
Pembrolizumab for advanced biliary adenocarcinoma: Results from the multicohort, phase II KEYNOTE-158 study.
29:viii210.
2018
-
Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data..
29 Suppl 8:viii461-viii462.
2018
-
Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial.
29:viii332.
2018
-
Phase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy..
29 Suppl 8:viii451-viii452.
2018
-
Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.
29:viii736.
2018
-
Prevalence of clinically actionable germline pathogenic variants (PVs) in advanced prostate cancer (aPC).
29:viii294.
2018
-
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer..
29:1541-1547.
2018
-
It is time to rethink weight loss in cancer..
29:1091-1092.
2018
-
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer..
29:1108-1119.
2018
-
Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG)..
29:857-871.
2018
-
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases..
29:959-965.
2018
-
Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?.
29:311-323.
2018
-
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet..
29:23-25.
2018
-
Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy..
29:244-249.
2018
-
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study..
29:154-161.
2018
-
A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance)..
28:2806-2812.
2017
-
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide..
28:2264-2271.
2017
-
Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer..
28:2272-2277.
2017
-
Statistical controversies in clinical research: data access and sharing-can we be more transparent about clinical research? Let's do what's right for patients..
28:1734-1737.
2017
-
Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC)..
28 Suppl 3:iii151.
2017
-
Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance)..
28:1359-1367.
2017
-
Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial..
28:1070-1077.
2017
-
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients..
28:1050-1056.
2017
-
Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies..
28:57-74.
2017
-
Next Steps in Immuno-Oncology: Enhancing Antitumor Effects Through Appropriate Patient Selection and Rationally Designed Combination Strategies.
2016
-
Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis..
27:1818-1828.
2016
-
Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial..
27:1579-1585.
2016
-
Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials..
27:1068-1074.
2016
-
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL..
27:286-294.
2016
-
Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors..
26:2125-2132.
2015
-
Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy..
26:1948-1953.
2015
-
Survival after resection of perihilar cholangiocarcinoma-development and external validation of a prognostic nomogram..
26:1930-1935.
2015
-
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015..
26:1589-1604.
2015
-
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration..
26:1280-1291.
2015
-
The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy..
26:1452-1458.
2015
-
Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors..
26:1230-1237.
2015
-
A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer..
26:762-768.
2015
-
EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity?.
26:548-555.
2015
-
Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†..
26:288-300.
2015
-
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA..
26:113-119.
2015
-
Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis..
25:2314-2327.
2014
-
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†..
25:1871-1888.
2014
-
1051PDIMMUNOMODULATORY ACTIVITY OF NIVOLUMAB IN PREVIOUSLY TREATED AND UNTREATED METASTATIC RENAL CELL CARCINOMA (MRCC): BIOMARKER-BASED RESULTS FROM A RANDOMIZED CLINICAL TRIAL..
25:iv362.
2014
-
795PA PROGNOSTIC MODEL FOR PREDICTING RADIOGRAPHIC PROGRESSION- FREE SURVIVAL (RPFS) IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER MEN TREATED WITH SECOND-LINE CHEMOTHERAPY..
25:iv276.
2014
-
Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome)..
25:1807-1812.
2014
-
Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer..
25:763-773.
2014
-
The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases..
25:182-188.
2014
-
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)..
24:2875-2880.
2013
-
The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials..
24:2475-2484.
2013
-
Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer..
24:2088-2092.
2013
-
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide..
24:1802-1807.
2013
-
Prospective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-cell lung cancer..
24:1630-1639.
2013
-
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation..
24:769-776.
2013
-
Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer..
24:420-428.
2013
-
Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907)..
23:3075-3081.
2012
-
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness..
23:2356-2362.
2012
-
Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer..
23:1803-1808.
2012
-
Third CECOG consensus on the systemic treatment of non-small-cell lung cancer..
23:1223-1229.
2012
-
Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840..
23:632-638.
2012
-
Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial..
23:688-694.
2012
-
Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience..
23:458-463.
2012
-
Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer..
22:2582-2590.
2011
-
Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck..
22:2501-2507.
2011
-
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers..
22:2304-2309.
2011
-
Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients..
22:2107-2112.
2011
-
The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG-PET or gallium-67 scans..
22:405-410.
2011
-
Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism..
21:2246-2254.
2010
-
Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer..
21:1302-1307.
2010
-
Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications..
21 Suppl 5:v248-v251.
2010
-
Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials..
21:312-318.
2010
-
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy..
21:319-324.
2010
-
Immune thrombocytopenic purpura (ITP) and breast cancer. Does adjuvant therapy for breast cancer improve platelet counts in ITP?.
20:1282-1283.
2009
-
Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer..
20:1223-1229.
2009
-
A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102..
20:1074-1079.
2009
-
Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens..
20:1026-1031.
2009
-
Hematopoietic growth factors: ESMO recommendations for the applications..
20 Suppl 4:162-165.
2009
-
Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer..
20:965-966.
2009
-
Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels..
19:1787-1794.
2008
-
Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma..
19:1650-1654.
2008
-
A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer..
19:1068-1074.
2008
-
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207..
19:946-950.
2008
-
Bayesian machine learning on CALGB/SWOG 80405 (Alliance) and PEAK data identify a heterogeneous landscape of clinical predictors of overall survival (OS) in different populations of metastatic colorectal cancer (mCRC).
2019
-
Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study.
2019
-
Phase I extension study of ETC-159 an oral PORCN inhibitor administered with bone protective treatment, in patients with advanced solid tumours
2018
-
A genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients.
2018
-
A pooled analysis of individual patient data (IPD) of concurrent chemoradiotherapy for limited-stage small cell lung cancer (LS-SCLC) in elderly compared to younger patients (pts) who participated in US National Cancer Institute cooperative group studies.
2018
-
A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC).
2018
-
An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC).
2018
-
Androgen decline and outcome in castration resistant prostate cancer (mCRPC) patients treated with docetaxel (Doc), prednisone +/- bevacizumab (B).
2018
-
Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA).
2018
-
Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1°) side-related angiogenic drivers of metastatic colorectal cancer (mCRC).
2018
-
Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: Results from S-TRAC trial.
2018
-
EXTEND: Safety and efficacy of exercise training in men receiving enzalutamide (ENZ) in combination with conventional androgen deprivation therapy (ADT) for hormone naïve prostate cancer (HSPC).
2018
-
Impact of initial treatment (tx) on HRQoL and outcomes in patients (pts) with newly diagnosed multiple myeloma (NDMM) without intent for immediate transplant (SCT): Results from the Connect® MM registry.
2018
-
NCI 9922: Phase II study of ibrutinib in treatment-refractory distant metastatic cutaneous melanoma (DMCM).
2018
-
Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1mg/kg + ipilimumab 3mg/kg expansion from CheckMate 032.
2018
-
Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial.
2018
-
PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials.
2018
-
QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset.
2018
-
Safety and efficacy of a DKK1 inhibitor (DKN-01) in combination with pembrolizumab (P) in patients (Pts) with advanced gastroesophageal (GE) malignancies.
2018
-
Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis.
2018
-
ABT-165 plus FOLFIRI vs bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab - Trial in progress.
2018
-
Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC).
2018
-
Variability of current global practice patterns in the management of metastatic colorectal cancer.
2018
-
Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study.
2017
-
1072PEXPERIENCE OF PATIENTS TREATED WITH SIPULEUCEL-T IN AN ACADEMIC SETTING.
2014
-
810ORANDOMIZED, DOSE-RANGING PHASE II TRIAL OF NIVOLUMAB FOR METASTATIC RENAL CELL CARCINOMA (MRCC).
2014